# Pattern Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pattern-bioscience

- Industry: Biotechnology
- Headquarters: Austin, US
- Website: www.pattern.bio
- Total disclosed funding: $36M
- Latest round: Series C (Dec 28, 2022)
- Investors on record: 4

## About

Based in the US, Pattern Bioscience Inc. is a biotechnology firm focused on innovative diagnostic solutions to combat antibiotic misuse in healthcare, enhancing patient care through rapid microbial identification and targeted treatments.Pattern Bioscience Inc., founded in 2016 and headquartered in Austin, US, specializes in diagnostic solutions for healthcare. The company was founded by Nick Arab and Ross Johnson. It has secured a total of 4 deals, with its most recent funding round being a Series C on December 28, 2022, raising USD 23.50 mn from investors including Illumina Ventures and Omnimed Capital, resulting in a total amount raised of USD 23.50 mn and a current company valuation of USD 86.41 mn.Pattern Bioscience offers innovative diagnostic solutions aimed at addressing the critical issue of antibiotic misuse in healthcare. Their core product utilizes single-cell microbiology, which allows for rapid identification and antimicrobial susceptibility testing (ID/AST) of bacterial pathogens within hours, significantly reducing the time associated with traditional culture-based methods. This technology decodes the metabolic patterns of individual bacterial cells, enabling clinicians to deliver targeted antibiotic treatments that improve patient outcomes and mitigate the development of antibiotic resistance. The company serves a diverse client base that includes hospitals, laboratories, and healthcare providers, primarily in North America and Europe, where the demand for faster and more accurate diagnostic tools is increasingly recognized. Their services cater to all common infection sites, addressing a pressing global health crisis by providing smarter, agile diagnostics.Pattern Bioscience generates revenue through a combination of direct sales and partnerships with healthcare institutions. The company offers its diagnostic solutions under a structured pricing model typically associated with B2B transactions, where hospitals and laboratories purchase the technology and associated services directly. Their flagship diagnostic platform, which includes the single-cell microbiology technology, may involve subscription agreements, allowing clients to access continuous updates and support services. Given the critical nature of their offerings, the transaction structure is designed to support long-term relationships with healthcare providers, fostering an ongoing commitment to improving patient care through advanced diagnostics.Following its most recent Series C funding round in December 2022, which raised USD 23.50 mn, Pattern Bioscience plans to utilize the funds to further develop its infectious diseases platform, continue its clinical validation studies, and regulate its diagnostic software. The company aims to expand into new markets, particularly targeting increased penetration in Europe and North America by the end of 2024.

## Funding rounds

- Series C, Dec 28, 2022, $24M — Illumina Ventures, Omnimed Capital, AMR Action Fund, Daleshaw
- Series B, Jul 14, 2020, $9M — Illumina Ventures, Omnimed Capital
- Series A, Mar 17, 2018, $3.6M — Omnimed Capital

## Investors

- Omnimed Capital (https://capitalatlas.ai/funds/omnimed-capital) — Series A, Series B, Series C
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series B, Series C
- AMR Action Fund (https://capitalatlas.ai/funds/amr-action-fund) — Series C
- Daleshaw — Series C